These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 10522686

  • 1. Localized lipoatrophy after glatiramer acetate injection in patients with remitting-relapsing multiple sclerosis.
    Drago F, Brusati C, Mancardi G, Murialdo A, Rebora A.
    Arch Dermatol; 1999 Oct; 135(10):1277-8. PubMed ID: 10522686
    [No Abstract] [Full Text] [Related]

  • 2. Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis.
    Soós N, Shakery K, Mrowietz U.
    Am J Clin Dermatol; 2004 Oct; 5(5):357-9. PubMed ID: 15554737
    [Abstract] [Full Text] [Related]

  • 3. Lobular panniculitis at the site of glatiramer acetate injections for the treatment of relapsing-remitting multiple sclerosis. A report of two cases.
    Ball NJ, Cowan BJ, Moore GR, Hashimoto SA.
    J Cutan Pathol; 2008 Apr; 35(4):407-10. PubMed ID: 18333902
    [Abstract] [Full Text] [Related]

  • 4. Lipoatrophy in patients with multiple sclerosis on glatiramer acetate.
    Edgar CM, Brunet DG, Fenton P, McBride EV, Green P.
    Can J Neurol Sci; 2004 Feb; 31(1):58-63. PubMed ID: 15038472
    [Abstract] [Full Text] [Related]

  • 5. Lipoatrophy associated with glatiramer acetate injections for the treatment of multiple sclerosis.
    Hwang L, Orengo I.
    Cutis; 2001 Oct; 68(4):287-8. PubMed ID: 11710450
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Development of myasthenia gravis in a patient with multiple sclerosis during treatment with glatiramer acetate.
    Frese A, Bethke F, Lüdemann P, Stögbauer F.
    J Neurol; 2000 Sep; 247(9):713. PubMed ID: 11081814
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Relapsing MS patients' experiences with glatiramer acetate treatment: a phenomenological study.
    Miller CE, Jezewski MA.
    J Neurosci Nurs; 2006 Feb; 38(1):37-41. PubMed ID: 16568812
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Copolymer-1 in the treatment of multiple sclerosis.
    Boyden KM.
    J Neurosci Nurs; 1998 Apr; 30(2):135-9; quiz 140-1. PubMed ID: 9642622
    [Abstract] [Full Text] [Related]

  • 20. [A place of first-line drugs in treatment of multiple sclerosis].
    Kasatkin DS.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016 Apr; 116(12):145-151. PubMed ID: 28635741
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.